Blood-Based Biomarker for Alzheimer’s Disease Diagnostics Market Trends, Share and Growth Analysis 2035
According to Payal Rabde, who specializes in the therapeutic area, mental health solutions, and disease diagnostics, with 4+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the blood-based biomarker for Alzheimer’s disease diagnostics market. The global blood-based biomarker for Alzheimer’s disease diagnostics market size was estimated at USD 169.27 million in 2025 and is predicted to increase from USD 198.72 million in 2026 to approximately USD 841.9 million by 2035, expanding at a CAGR of 17.4% from 2026 to 2035. Her analysis highlights that the market is growing due to R&D activities and government support in mental health. The research also examines the competitive strategies of key industry participants, including Roche Diagnostics, Fujirebio,nC2N Diagnostics, Quanterix, Quest Diagnostics, Labcorp, Eli Lilly & Co., etc.
Last Updated : 09 September 2026
Category: Diagnostics
Insight Code: 6797
Format: PDF / PPT / Excel